Clinical Data gets app nod for depression drug

May 24, 2010

(AP) -- Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said Monday.

The acceptance of vilazodone, officially made Friday by the , triggered a $15.6 million payment by Clinical Data to Merck Serono, which developed the drug.

In June 2009, Clinical Data said vilazodone met its goals in a late-stage clinical trial as a treatment for major .

Merck Serono is a unit of German drug maker Merck KGaA, and is not connected to New Jersey-based Merck and Co.

shares

Related Stories

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.